Mortality in systemic sclerosis: Lessons learned from population-based and observational cohort studies

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 131-137

  Nikpour, Mandana ^a   Baron, Murray ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

mortality; systemic sclerosis

Indexed keywords

CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MALE; META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDY AS TOPIC; ORGAN SPECIFICITY; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84894042138     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000027     Document Type: Review

References (39)

1. Elhai M, Meune C, Avouac J, Kahan A, et al. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-Analysis of cohort studies. Rheumatology (Oxford) 2012; 51:1017-1026
2. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1997-2002. Ann Rheum Dis 2007; 66:940-944
4. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-Associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-157
5. Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in scleroderma. Ann Rheum Dis 1971; 30:581-588
6. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, et al. Survival with systemic sclerosis (scleroderma): A life-Table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75:369-376
7. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15:276-283
8. Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: Mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988; 18:1-13
9. Clements PJ, Lachenbruch PA, Ng SC, et al. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990; 33:1256-1263
10. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34:403-413
11. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82:139-148
12. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: A comparison with the general population. J Rheumatol 1995; 22:2100-2102
13. Bryan C, Howard Y, Brennan P, et al. Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35:1122-1126
14. Bond C, Pile KD, McNeil JD, et al. South Australian Scleroderma Register: Analysis of deceased patients. Pathology 1998; 30:386-390
15. Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, et al. Survival, causes of death, and prognostic factors in systemic sclerosis: Analysis of 947 Brazilian patients. J Rheumatol 2012; 39:1971-1978
16. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118:602-609
17. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42:2660-2665
18. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28:2454-2459
19. Kerneis S, Boelle PY, Grais RF, et al. Mortality trends in systemic sclerosis in France and USA, 1980-1998: An age-period-cohort analysis. Eur J Epidemiol 2010; 25:55-61
20. Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study. QJM 2010; 103:109-115
21. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: An international meta-Analysis of individual patient data. Am J Med 2005; 118:2-10
22. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-686
23. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37:750-755
24. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154-167
25. Simeon CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42:71-75
26. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 2002; 81:139-153
27. Mok CC, Chan PT, Chan KL, Ma KM. Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: A case-control study. Rheumatology (Oxford) 2013; 52:296-303
28. Chan PT, Mok CC. Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis. Clin Rheumatol 2012; 31:1273-1277
29. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: Improved survival in the current era. Heart 2006; 92:926-932
30. Johnson SR, Swiston JR, Granton JT. Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. J Rheumatol 2008; 35:1584-1590
31. Lefevre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-Associated pulmonary hypertension: A systematic review and meta-Analysis. Arthritis Rheum 2013; 65:2412-2423
32. Ngian GS, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-Associated pulmonary arterial hypertension: A cohort study. Arthritis Res Ther 2012; 14:R213
33. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis Rheum 2009; 60:569-577
34. Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: Histopathology, clinical features, and survival. Chest 2008; 134:601-605
35. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52:155-160
36. Komocsi A, Vorobcsuk A, Faludi R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: A systematic review and metaanalysis of observational studies. Rheumatology (Oxford) 2012; 51: 1027-1036
37. Beretta L, Santaniello A, Cappiello F, et al. Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. Clin Exp Rheumatol 2010; 28:S18-S27
38. Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: Validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70:1788-1792
39. Ngian GS, Sahhar J, Wicks IP, Van Doornum S. Cardiovascular disease in systemic sclerosis: An emerging association? Arthritis Res Ther 2011; 13:237